Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Thursday, March 21st. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.24. On average, analysts expect Mineralys Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Mineralys Therapeutics Stock Down 1.1 %
NASDAQ:MLYS traded down $0.14 during trading hours on Friday, reaching $12.95. 71,802 shares of the company's stock were exchanged, compared to its average volume of 155,758. The company has a market capitalization of $642.71 million, a P/E ratio of -6.55 and a beta of 2.05. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $17.70. The business's 50-day simple moving average is $13.08 and its two-hundred day simple moving average is $10.49.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on MLYS shares. Lifesci Capital restated an "outperform" rating on shares of Mineralys Therapeutics in a report on Tuesday, March 26th. The Goldman Sachs Group started coverage on Mineralys Therapeutics in a report on Tuesday, April 2nd. They issued a "buy" rating and a $30.00 target price for the company.
Check Out Our Latest Analysis on MLYS
Insider Activity
In other news, major shareholder Samsara Biocapital Gp, Llc acquired 555,555 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average price of $13.50 per share, with a total value of $7,499,992.50. Following the completion of the transaction, the insider now owns 5,074,916 shares in the company, valued at $68,511,366. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 33.24% of the stock is owned by corporate insiders.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
